Electroporation (EP)-related technical errors experienced during an HIV vaccine clinical trial conducted in Rwanda and Uganda: lessons learned by R Bayingana et al.
POSTER PRESENTATION Open Access
Electroporation (EP)-related technical errors
experienced during an HIV vaccine clinical
trial conducted in Rwanda and Uganda:
lessons learned
R Bayingana1*, A Nanvubya2, E Karita1, J Nyombayire1, R Ingabire1, K Chinyenze3, J Lehrman3, C Schimidt3,
D Hannaman4, S Allen5, P Fast3
From AIDS Vaccine 2012
Boston, MA, USA. 9-12 September 2012
Background
Intracellular DNA vaccine delivery is essential for antigen
expression and induction of immune response. Unfortu-
nately, conventional intramuscular injection provides low
efficiency DNA uptake and suboptimal immunogenicity.
Electroporation-based DNA vaccination can enhance
potency by 100-1000 fold. In this trial we used the TriGrid
Delivery System by Ichor Medical Systems. We describe
the electroporation technical errors that occurred during
administration of an HIV pDNA vaccine in a clinical trial
conducted at sites in Rwanda and Uganda and how those
errors were resolved.
Methods
The site physicians were trained and qualified to use the
EP procedure during site initiation visits and further prac-
ticed mock EPs later. We examined the technical errors
that occurred by reviewing volunteer files between 19th
December 2011 and 27th March 2012.
Each administration of the HIV pDNA intramuscularly
by electroporation required two injections (one in each del-
toid muscle) at each vaccination time point. Should an
error occur during EP procedure, the respective error codes
are shown on the monitor. Once the procedure is complete,
‘procedure complete’ is indicated on the monitor.
Results
Six errors out of 90 eletroporations occurred. Four
occurred because of improper insertion of the electrodes
or injection needle. These errors were resolved by
repeating the procedure. Two occurred because of
improper insertion of the cartridge into the applicator
and on both occasions the errors were captured before
switching on the enable button on the pulse stimulator.
These were resolved by properly re-inserting the car-
tridge into the applicator. Most of the other potential
errors were caught before the procedure started by the
second person observing the set up.
Conclusion
We conclude that errors related to EP procedure can be
minimized or avoided when there is appropriate quality
control immediately prior to vaccination. We advise to
have two trained and qualified staff present during the
procedure for quality control purposes.
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